There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .
Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease.
Although nonalcoholic steatohepatitis ( NASH ) has generally been considered a benign condition , the increasing prevalence and severity of obesity has heightened concerns about the frequency with which NASH progresses to end-stage liver disease . The aim of this study is to determine the frequency , clinical features , and posttransplantation history of decompensated liver disease secondary to NASH . The frequency of NASH as a cause of end-stage liver disease was prospect ively determined in patients evaluated for liver transplantation . NASH was considered to be the primary cause of liver disease in patients who had histological evidence of steatohepatitis and in whom chronic liver diseases other than NASH were excluded .  Posttransplantation histological characteristics were also determined in patients with NASH and compared with those of patients with pretransplantation diagnoses of cholestatic liver diseases , alcoholic disease , and hepatitis C. Of 1,207 patients evaluated for liver transplantation during the study period , 31 patients ( 2.6 % ) had NASH as the primary cause of liver disease . In the same period , 546 liver transplantations were performed , 16 of which ( 2.9 % ) were for end-stage disease secondary to NASH . Posttransplantation steatosis was seen in 60 % of transplant recipients with NASH versus 5 % of those with cholestatic disease , 15 % of those with alcoholic disease , and 15 % of those with hepatitis C. Steatohepatitis recurred in 33 % of transplant recipients with NASH , with progression to cirrhosis in 12.5 % . NASH can progress to end-stage liver disease in a minority of affected patients and was the primary cause of liver disease in 2.9 % of patients evaluated for liver transplantation at our center . Recurrence of steatosis and NASH is frequent and can be severe after liver transplantation
There was no significant change in the γGT levels .
Significant differences were not found .
CONCLUSION Silymarin minimally reduced , but without clinical relevance , the serum levels of ALT and AST .
AIM To evaluate the effect of silymarin on the serum levels of alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) and gamma glutamyl transpeptidase ( γGT ) in patients with liver diseases .